版本:
中国

BRIEF-Nymox reports additional positive data from fexapotide BPH phase 3 trial

Nov 29 Nymox Pharmaceutical Corp :

* Nymox reports additional positive results from completed fexapotide BPH phase 3 studies showing significant early response and first-line efficacy

* New phase 3 results indicate that fexapotide in trials was highly efficacious for first-line treatment of BPH Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐